Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 10, 2026
PepsiCo (PEP) Delivers 6.4% Revenue Growth in Q2 While Affirming 2026 Outlook

PepsiCo (PEP) Delivers 6.4% Revenue Growth in Q2 While Affirming 2026 Outlook

Key Takeaways

  • PepsiCo reported net revenue of $24.18 billion for the second quarter, up 6.4% year over year and ahead of analyst expectations.
  • Adjusted earnings per share came in at $2.20, slightly below the $2.21 consensus estimate but up 4% from the prior year on a core basis.
  • Organic revenue grew 2.4%, driven by effective net pricing and modest volume gains, with international segments showing strong performance.
  • North American convenient foods and beverages faced pressure from tighter consumer budgets amid inflation.
  • The company affirmed its full-year 2026 guidance for organic revenue growth of 2% to 4% and core constant currency EPS growth of 4% to 6%.
  • Shares declined following the report as investors focused on domestic softness despite the revenue beat.

Putting the Results in Context

PepsiCo’s second-quarter results offer a clear window into consumer spending patterns in its largest market and the progress of its global expansion efforts. The company follows a calendar fiscal year and reported results for the 12 weeks ended June 13, 2026. Recent periods have highlighted resilience in international operations that has helped offset softer demand in the U.S., making this report a useful check on whether productivity initiatives and product innovation can maintain momentum despite macroeconomic pressures.

Breaking Down the Quarter’s Numbers

PepsiCo posted net revenue of $24.18 billion, a 6.4% increase from $22.73 billion a year earlier and above Wall Street forecasts of approximately $23.97 billion. Organic revenue rose 2.4%, supported by net pricing and volume contributions. GAAP earnings per share surged 137% to $2.18, while core EPS advanced 4% to $2.20, just missing the $2.21 consensus. Core constant currency EPS increased 1%. Operating profit grew significantly due to the absence of prior-year impairment charges, though core operating margin contracted 40 basis points. The company reaffirmed its fiscal 2026 outlook for organic revenue growth of 2% to 4% and core constant currency EPS growth of 4% to 6%.

Market Reaction and Investor Sentiment

Shares of PEP fell in after-hours trading following the release, reflecting investor disappointment with the slight EPS miss and continued softness in North American categories. Analysts noted that while revenue exceeded expectations, domestic volume trends and margin pressure weighed on sentiment. Pre-earnings positioning had been cautious amid broader consumer staples weakness, and the mixed results reinforced concerns about U.S. spending resilience.

Forward Outlook and Factors to Watch

Investors will focus on PepsiCo’s ability to sustain international momentum while addressing North American challenges. Management highlighted ongoing innovation in functional and permissible products, affordability initiatives, and productivity efforts to improve operating leverage. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Upcoming catalysts include third-quarter volume trends across segments and updates on brand restaging programs. Cost inflation, foreign exchange movements, and consumer response to pricing actions remain important variables.

Guidance affirmation suggests management views the current environment as manageable, but execution on productivity and portfolio evolution will be closely watched in coming quarters. Free cash flow conversion and capital spending discipline also merit attention as the company navigates a dynamic demand landscape.

Enhancing Research with AI Tools

When analyzing results like these, I find it helpful to cross-reference with Tickeron’s AI Screener. It is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. AI Screener

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations
Related Ticker: PEP

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


PEP's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for PEP turned positive on July 27, 2026. Looking at past instances where PEP's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 27, 2026. You may want to consider a long position or call options on PEP as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PEP advanced for three days, in of 306 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 65 cases where PEP's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

PEP moved below its 50-day moving average on July 30, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PEP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PEP broke above its upper Bollinger Band on July 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for PEP entered a downward trend on July 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.554) is normal, around the industry mean (5.764). P/E Ratio (18.144) is within average values for comparable stocks, (42.903). Projected Growth (PEG Ratio) (1.499) is also within normal values, averaging (4.589). PEP has a moderately high Dividend Yield (0.041) as compared to the industry average of (0.026). P/S Ratio (1.958) is also within normal values, averaging (2.926).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. PEP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PEP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.

Notable companies

The most notable companies in this group are Coca-Cola Company (NYSE:KO), PepsiCo (NASDAQ:PEP).

Industry description

Non-alcoholic drinks include traces of alcohol or low alcohol content or without alcohol or alcohol removed. Functional Beverages, Carbonated Soft Drinks (CSDs), Sports Drinks, Fruit Beverages, and Bottled Water are some common types of non-alcoholic beverages. The largest segment in this market is soft drinks (think Pepsi and Coke). Many established companies in this space have also been stepping up production of low to zero-calorie varieties in recent years, to cater to a rising number of health-conscious consumers. Coca-Cola Company, Pepsico Inc, Keurig Dr Pepper Inc. and Monster Beverage Corporation are some major non-alcoholic beverage makers.

Market Cap

The average market capitalization across the Beverages: Non-Alcoholic Industry is 47.26B. The market cap for tickers in the group ranges from 1.77K to 373.68B. KO holds the highest valuation in this group at 373.68B. The lowest valued company is BVNNF at 1.77K.

High and low price notable news

The average weekly price growth across all stocks in the Beverages: Non-Alcoholic Industry was -4%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -11%. BUDA experienced the highest price growth at 7%, while SUJA experienced the biggest fall at -38%.

Volume

The average weekly volume growth across all stocks in the Beverages: Non-Alcoholic Industry was 78%. For the same stocks of the Industry, the average monthly volume growth was 61% and the average quarterly volume growth was 30%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 65
Price Growth Rating: 60
SMR Rating: 61
Profit Risk Rating: 73
Seasonality Score: -32 (-100 ... +100)
View a ticker or compare two or three
PEP
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a provider of a diversified line of soft drinks and snack foods

Industry BeveragesNonAlcoholic

Profile
Details
Industry
Beverages Non Alcoholic
Address
700 Anderson Hill Road
Phone
+1 914 253-2000
Employees
306000
Web
https://www.pepsico.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.